Clinical Trials Logo

PCSK9 clinical trials

View clinical trials related to PCSK9.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04759534 Active, not recruiting - Clinical trials for Heterozygous Familial Hypercholesterolemia

Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

Start date: September 10, 2020
Phase: Phase 3
Study type: Interventional

This study plans to enroll several patients with heterozygous familial hypercholesterolemia, randomly assigned to different dose groups, and randomly receiving subcutaneous injection of IBI306150 mg or placebo every two weeks: or subcutaneous injection of IBI306 450mg every four weeks (n=49) or placebo (n=25) treatment, treatment lasted for 12 weeks. During randomization, the LDL-C level (<4.8mmol/L or ≥4.8mmol/L) observed during the screening period visit (VI), and whether ezetimibe was used for stratification. After 12 weeks, each group entered the 12-week open-period treatment, in which subjects in the IBI306 group continued to receive IBI306 treatment, and subjects in the placebo group stopped using placebo and received IBI306 treatment. The exploratory endpoint is the population pharmacokinetic characteristics of IBI306 in Chinese heterozygous familial hypercholesterolemia population.